GEN Exclusives

More »

GEN News Highlights

More »
Apr 15, 2009

Sanofi-Aventis to Acquire BiPar in Deal Valued at $500M

Sanofi-Aventis to Acquire BiPar in Deal Valued at $500M

Sanofi agrees to pay BiPar provided milestones are met

  • Sanofi-aventis signed a binding agreement to acquire BiPar Sciences in a deal worth up to $500 million. The purchase price will depend on milestones achieved by BiPar's lead candidate, BSI-201, a potential first-in-class PARP inhibitor.

    BSI-201 is currently in Phase II trials. It is being investigated in metastatic triple negative breast cancer (TNBC), ovarian cancer, and other malignancies. PARP inhibitors reportedly prevent cancer cells from repairing their own DNA and ultimately cause cancer cell death.

    "The acquisition of BiPar, one of the pioneers for novel tumor-selective therapies, is a further step in our company's goal to focus on new approaches to strengthen our oncology R&D portfolio," says Christopher A. Viehbacher, CEO of Sanofi. "This acquisition illustrates our strong commitment to oncology to provide patients, physicians, and public health stakeholders with breakthrough medicines addressing unmet medical needs."

    BSI-201 is a targeted cancer therapy based on an emerging technique called PARP inhibition, says BiPar. The drug is reportedly being studied in breast and ovarian cancer as well as other malignancies.


    ---

    Related News
    Sanofi-Aventis to Commercialize AEterna Zentaris’ Late-Stage BPH Drug in the U.S. (Mar. 6, 2009)
    Sanofi-Aventis Ups Bid for Zentiva to $2.63B (Sept. 22, 2008)
    Dyax and Sanofi-Aventis Ink Oncology Antibody Deal Worth $500M (Feb. 12, 2008)
    Sanofi-aventis Inks Partnership with Regeneron Valued at $560M (Nov. 29, 2007)
    BiPar Finds Overexpressed Protein in Specific Cancers (Oct. 26, 2007)



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?